Successful Treatment of Crizotinib-Induced Fulminant Liver Failure: A Case Report and Review of Literature

Crizotinib is a first-line tyrosine kinase inhibitor used for the treatment of metastatic lung cancer. Crizotinib-induced hepatotoxicity is a rare event. We report a case of a 46-year-old female with a history of metastatic lung cancer who presented with acute liver failure after being on crizotinib...

Full description

Saved in:
Bibliographic Details
Main Authors: Kyle Kreitman, Satheesh P. Nair, Jiten P. Kothadia
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Case Reports in Hepatology
Online Access:http://dx.doi.org/10.1155/2020/8247960
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Crizotinib is a first-line tyrosine kinase inhibitor used for the treatment of metastatic lung cancer. Crizotinib-induced hepatotoxicity is a rare event. We report a case of a 46-year-old female with a history of metastatic lung cancer who presented with acute liver failure after being on crizotinib for two months. The medication was discontinued, and she was treated with N-acetylcysteine for seven days. Her liver function tests returned to normal limits after 26 days after admission. The precise mechanism and risk factors of crizotinib-induced hepatotoxicity remain unknown. Physicians should be aware of the potentially lethal side effect caused by crizotinib.
ISSN:2090-6587
2090-6595